High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.
High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.